1307 related articles for article (PubMed ID: 21704233)
1. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
4. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
Weiss IA; Valiquette G; Schwarcz MD
Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
[TBL] [Abstract][Full Text] [Related]
5. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
[TBL] [Abstract][Full Text] [Related]
6. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
Blonde L
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
[TBL] [Abstract][Full Text] [Related]
7. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
Roman G; Hancu N
Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
10. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
Ametov AS; P'ianykh OP; Chernikova NA
Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
[TBL] [Abstract][Full Text] [Related]
11. Effect of a multifactorial intervention on mortality in type 2 diabetes.
Gaede P; Lund-Andersen H; Parving HH; Pedersen O
N Engl J Med; 2008 Feb; 358(6):580-91. PubMed ID: 18256393
[TBL] [Abstract][Full Text] [Related]
12. Incretin therapy for type 2 diabetes mellitus.
Klonoff DC
Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
[TBL] [Abstract][Full Text] [Related]
13. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
Ma J; Yang W; Fang N; Zhu W; Wei M
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
[TBL] [Abstract][Full Text] [Related]
14. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
[TBL] [Abstract][Full Text] [Related]
15. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
[TBL] [Abstract][Full Text] [Related]
16. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
18. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.
Bangalore S; Kumar S; Lobach I; Messerli FH
Circulation; 2011 Jun; 123(24):2799-810, 9 p following 810. PubMed ID: 21632497
[TBL] [Abstract][Full Text] [Related]
20. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials.
Hopper I; Billah B; Skiba M; Krum H
Eur J Cardiovasc Prev Rehabil; 2011 Dec; 18(6):813-23. PubMed ID: 21878448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
